Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
LEXINGTON, Mass., Aug. 02, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, and Darlene Deptula-Hicks, SVP and chief financial officer, are scheduled to attend and present at the 37th Annual Canaccord Genuity Growth Conference. The conference is being held August 9-10, 2017 at the InterContinental Hotel in Boston, MA.
Management is scheduled to present on Wednesday, August 9, 2017 at 11:00 a.m. ET and will be available for one-on-one meetings during the conference. The presentation will be webcast live and available for replay and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days following the presentation.
About T2 Biosystems
T2 Biosystems is dedicated to developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.
Company Contact: Darlene Deptula-Hicks, T2 Biosystems SVP & Chief Financial Officer [email protected] 603-553-5803 Media Contact: Matthew McKillip, T2 Biosystems [email protected] 518-577-3466 Investor Contact: Chris Brinzey, Westwicke Partners [email protected] 339-970-2843
